Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Haemonetics (HAE – Research Report), Repligen (RGEN – Research Report) and Ginkgo Bioworks Holdings (DNA – Research Report).
Haemonetics (HAE)
In a report released today, Joanne Wuensch from Citi maintained a Hold rating on Haemonetics, with a price target of $94.00. The company’s shares closed last Friday at $89.58.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics with a $109.50 average price target.
See today’s best-performing stocks on TipRanks >>
Repligen (RGEN)
Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Repligen today. The company’s shares closed last Friday at $159.01.
According to TipRanks.com, Nowak has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Repligen has an analyst consensus of Strong Buy, with a price target consensus of $199.83.
Ginkgo Bioworks Holdings (DNA)
BTIG analyst Mark Massaro reiterated a Buy rating on Ginkgo Bioworks Holdings today and set a price target of $2.50. The company’s shares closed last Friday at $1.81.
According to TipRanks.com, Massaro has 0 stars on 0-5 stars ranking scale with an average return of
Ginkgo Bioworks Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $4.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HAE:
- Haemonetics announces European expansion for Vascade MVP
- Haemonetics price target raised to $114 from $111 at Barrington
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c
